Employment Type : Full-Time
Who We Are Enzyvant is a biotechnology company dedicated to developing novel, transformative regenerative therapies for people with devastating rare diseases. Enzyvant’s lead asset is the investigational tissue-based regenerative therapy, RVT-802, for congenital athymia, an ultra-rare and life-threatening pediatric immunodeficiency. RVT-802 has been granted multiple regulatory designations, including the US Food and Drug Administration expedited designation as a Regenerative Medicine Advanced Therapy (RMAT). Enzyvant is part of Sumitovant Biopharma (wholly owned by Sumitomo Dainippon Pharma), a global ecosystem of companies working on innovative research and development activities to transform healthcare and improve the lives of people worldwide. This global ecosystem has a geographic footprint spanning Japan, the US, China and the EU as well as talent, knowledge and resources across a wide spectrum of technologies and therapeutic areas. The Process and Analytical Development Scientist will be a key member of the CMC team. They will be responsible for helping establish the newly created Enzyvant Analytical and Process Development laboratory and driving process and analytical development initiatives. The Process and Analytical Development Scientist will have a lead role in processing human thymus tissue to support development activities. The candidate must have expertise in cell culture, tissue culture (preferred), or processing tissue for regenerative medicine. This role will design and lead studies aimed at process improvements for the slicing and culturing of human organs. You will: Qualifications Skills chiORee7o0